ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation

Wang, Qianyu; Shen, Xiaofei; Chen, Gang*; Du, Junfeng*南方医科大学; 南京大学; 1; 5
International Journal of Cancer2023-8-15DOI: 10.1002/ijc.34464
1被引5阅读
引用收藏
分享

摘要

Immunotherapy, especially with immune checkpoint inhibitors (ICIs), has shown advantages in cancer treatment and is a new hope for patients who have failed multiline therapy. However, in colorectal cancer (CRC), the benefit is limited to a small subset of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic CRC (mCRC). In addition, 45% to 60% of dMMR/MSI-H mCRC patients showed primary or acquired resistance to ICIs. This means that these patients may have potential unknown pathways mediating immune escape. Almost all mismatch repair-proficient (pMMR) or microsatellite-stable (MSS) mCRC patients do not benefit from ICIs. In this review, we discuss the mechanisms of action of ICIs and their current status in CRC. We then discuss the mechanisms of primary and acquired resistance to ICIs in CRC. Finally, we discuss promising therapeutic strategies to overcome resistance to ICIs in the clinic.

学科与关键词

关键词
immune checkpoint inhibitorsdrug resistancecolorectal cancermechanismtreatment
相关
加载中…
  • Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
    Du, Fenqi; Liu, Yanlong*Journal of Clinical Laboratory Analysis, 2022, 36(1): e24141.被引 9
  • Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis
    Wang, Ren; Lian, Jie; Wang, Xin; Pang, Xiangyi; Xu, Benjie; Tang, Shuli; Shao, Jiayue; Lu, Haibo*BIOMOLECULES AND BIOMEDICINE, 2023, 23(2): 198-208.被引 4
  • Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy
    Bai, Ziyi; Zhou, Yao; Ye, Zifan; Xiong, Jialong; Lan, Hongying; Wang, Feng*Frontiers in Immunology, 2022, 12: 808964.被引 49
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Cancer
发表日期
2023-08-15
卷期
第 153 卷, 第 4 期
页码
709-722
DOI
10.1002/ijc.34464
语言
MULTI-LANGUAGE
成果收录
SCIE

作者

  • W

    Wang, Qianyu (第一作者)

    2 · shanxi med univ · 1 · chinese peoples liberat army gen hosp

  • S

    Shen, Xiaofei

    nanjing univ

查看全部 4 位作者收起作者
  • C

    Chen, Gang (通讯)

    1 · chinese peoples liberat army gen hosp · 5

  • D

    Du, Junfeng (通讯)

    1 · chinese peoples liberat army gen hosp · 2 · southern med univ · 5

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417